The cardioprotective role of NACA in the prevention of Doxorubicin and Trastuzumab mediated cardiac dysfunction
Rationale: In the breast cancer setting, anti-cancer therapies, including Doxorubicin (DOX) and Trastuzumab (TRZ), are associated with an increased risk of cardiotoxicity. There is a need to develop prophylactic cardioprotective agents to mitigate the cardiotoxic side effects of these common anti-ca...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2015
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1993/30722 |